Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

OptiBiotix Health sweetener performs well in independent taste test

The company is developing sweet, natural, healthy fibres which are not digested in the human gut, and are therefore calorie-free
sugar cubes
The sweetener market is still dominated by sugar

An independent study has shown a sweetener developed by OptiBiotix Health PLC (LON:OPTI) scored well against competitors.

The Flavour and Sensory Science Centre at the University of Reading tested eight different samples.

It found the company's oligosaccharides were significantly sweeter than the other products tested, while being low in all “off-flavours” such as bitterness, sourness, staleness and saltiness.

The company is developing sweet, natural, healthy fibres under the SweetBiotix brand, which are not digested in the human gut, and are therefore calorie-free. 

Big potential market 

This would give the research firm entry to the US$100bn a year global sweetener market, which is still dominated by sugar.

OptiBiotix chief executive Stephen O'Hara said he was pleased with the results of the Reading study.

“This development creates the potential to replace existing unhealthy sugars with low calorie, healthy non-digestible fibres (SweetBiotix) with gut microbiome functionality.

“With growing concerns over the impact on health of traditional sugars and artificial sweeteners, the ability to develop sweet functional fibres puts OptiBiotix at the forefront of product development in this area of growing industry and commercial interest."

Human microbiome

The company’s specialism is the human microbiome, an ecosystem of bacteria and yeasts that reside in the gut and on the skin.

It is thought changes to the human flora can have an impact on health, hence the proliferation of functional foods such as yoghurts filled with probiotic, or good bacteria.

OptiBiotix’s focus is mainly on the gut with advances designed to tackle obesity, cholesterol and diabetes although the company does have a separately-quoted business developing skincare products.

In a note to clients, analysts at ‘house’ broker finnCap commented: “This positive taste study further demonstrates the potential for SweetBiotix to replace traditional sugars and artificial sweeteners as a bulk sugar replacement that contains no calories and improves microbiome diversity.”

In late afternoon trading, shares in Optibiotix were 1.6% higher at 635p.

--- Updates share price ---

View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

1527682514_angel-delight.jpg
May 30 2018
The latest fundraiser underscores the fact the life sciences business is well supported in the City
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
Workers at CERN
August 02 2018
Private banks and healthcare groups took part in the share placing

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use